Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

NCSP cargo turnover up 24% in the first half of the year

7/19/23 FESH

Inter RAO to buy the largest manufacturer of steam turbines

7/19/23 IRAO

Headhunter receipts will continue to trade on the Moscow Exchange until September 30th

7/19/23 HEAD

Etalon to delist from LSE

7/19/23 ETLN

Transneft reported for 6 months of 2023 by RAS

7/18/23 TRNFP

Cherkizovo Group reported for 6 months of 2023 by RAS

7/18/23 GCHE

RussNeft reported for 6 months of 2023 by RAS

7/18/23 RNFT

OGK-2's output in 1H increased by 5.7%

7/18/23 OGKB

The Morgan Stanley announced a quarterly dividend

7/18/23 MS

Morgan Stanley reported for 6 months of 2023

7/18/23 MS